Divya A., Veda N. Shetageri, Vinod K Mathew
Divya A.1, Dr. Veda N. Shetageri2, Vinod K Mathew3
1Department of Pharmacy Practice, Krupanidhi College of Pharmacy, Bangalore - 560035, Karnataka, India.
2Department of Pharmacy Practice, Faculty of Pharmacy, Krupanidhi College of Pharmacy, Bangalore - 560035, Karnataka, India.
3Department of Pharmacy Practice, Krupanidhi College of Pharmacy, Bangalore-560035, Karnataka, India.
Volume - 14,
Issue - 3,
Year - 2021
Objectives: To review the drug utilization and evaluation pattern of olanzapine and assessment of adverse drug reaction associated in psychotic patients in a tertiary care hospital. Methodology: A prospective Observational study was conducted in Department of Psychiatry, MVJ Medical College and Research Hospital, Bangalore, South India. Study was conducted for 6 months in In-patients who are diagnosed as suffering from psychosis which includes schizophrenia, delusional disorders, schizo-affective disorders, acute and transient psychosis and BPAD as per ICD 10 criteria. The utilization pattern of olanzapine therapy were assessed using case record forms with overall demographic data information was collected and ADR is assessed using standard scales. Result: Among 108 patients enrolled into the study 68 patients were under olanzapine therapy and rest were under other antipsychotics. A total of 68 patients olanzapine therapy patients out of which 51%were females and 49% were males. Majority of the patients belong to the age group of 28-37years and 18-27 years and 66% patients were married. Schizophrenia was found to be the common type of psychotic disorders with 63%. Even among the various psychotic disorders there was a slight female predominance. The hospitalization period was 12.43±8.4days. Majority of the patients had normal body mass index. Out of 68 patients 16 patients had switch over from olanzapine to other second-generation antipsychotics. Conclusion: This study has assessed for prescribing pattern of olanzapine in psychotic patients using a specially modified case reporting form. Olanzapine is most commonly prescribed antipsychotic compared to other antipsychotics for the treatment of paranoid schizophrenia and also in certain cases of bipolar affective disorder with mania or mixed episodes. Maximum patients were having paranoid schizophrenia.
Cite this article:
Divya A., Veda N. Shetageri, Vinod K Mathew. Drug Utilization Evaluation of Olanzapine and Assessment of Adverse Drug Reactions associated in Psychotic patients in a Tertiary Care Hospital. Research J. Pharm. and Tech 2021; 14(3):1395-1399. doi: 10.5958/0974-360X.2021.00249.3
1. Mackin P, Thomas SH. Atypical antipsychotic drugs. Bmj. 2011 Mar 4; 342:d1126. "NDA 21-520" Food and Drug Administration. 2003-12-24.
2. Canadian Agency for Drugs and Technologies in Health. A systematic review of combination and high-dose atypical antipsychotic therapy in patients with schizophrenia. Ottawa (CAN): CADTH. 2011.
3. Burns T, Christova L, Cooper S, Harrison L, Mckendrick J, Laugharne R et al. Maintenance antipsychotic medication pattern in outpatients Schizophrenia patients: a naturalistic cohort study. Acta Psychiatr Scand 2006 Feb;113(2):126-134.
4. Essock SM. Antipsychotic prescribing practices. Schizophrenia Bulletin 2002;28(1):1-4.
5. Clark RE, Bartels SJ, Mellman TA, Peacock WA. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorders: Implications for state mental health policy. Schizophrenia Bulletin 2002;28(1):75-84
6. "NDA 20-592 / S-019" . Food and Drug Administration. 2004-01-14.
7. Pillarella J, Higashi A, Alexander GC, Conti R (2012). "Trends in the use of atypical antipsychotics for the treatment of bipolar disorder in the United States, 1998-2009". Psychiatric Services. 63 (1): 83–86.
8. Bobo WV, Shelton RC (2009). "Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues". Neuropsychiatric Disease and Treatment. 5: 369–83.
9. "NDA 20-592" . Food and Drug Administration. 1996-09-06.
10. "Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa". U.S. Justice Department. 2009-01-15.
11. Mortimer AM. How do we choose between atypical antipsychotics? The advantages of amisulpride
12. Erickson KK, Zhu J, Lazarus P. Olanzapine metabolism and the significance of the UGT1A448V and UGT2B1067Y variants. Pharmacogenetics and genomics. 2011 Sep;21(9):539.
13. Komossa K, Rummel‐Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews. 2010(3).
14. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatric Services. 2004 Feb;55(2):151-6.
15. Srivastava A. Marriage as a perceived panacea to mental illness in India: Reality check. Indian Journal of Psychiatry. 2013 Jan; 55(Suppl 2) :S239.
16. Thara R, Srinivasan TN. Marriage and gender in schizophrenia. Indian J Psychiatry 1997; 39:64-9.
17. Thara R, Padmavathi R, Lakshmi A, Karpagavalli P. Family education in schizophrenia: A comparison of two approaches. Indian J Psychiatry 2005;47(4):218 – 21.
18. Ponnudurai R, Jayakar J, Sekar BS. Assessment of mortality and marital status of schizophrenic patients over a period of 13 years. Indian J Psychiatry 2006; 48:84-87.
19. Thaker G, Admi H, Moran M, Lathi A, Cassady S. Psychiatric illnesses in families of subjects with schizophrenia – spectrum personality disorders: High morbidity risks for unspecified functional psychosis and schizophrenia. Am J Psychiatry 1993; 150:66-71.
20. Dutta SB, Dhasmana DC, Bhardwaj R. Psychotropic drug utilization pattern among patients with schizophrenia. Indian J Psychiatry 2005; 47(4):243 – 44.
21. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration – New York metropolitan region. Schizophrenia Bulletin 2002; 28(1):31-42.
22. Acquaviva E, Gansquet L, Falissard B. Psychotropic combination in schizophrenia. Eur J Clin Pharmacol 2005; 61:855-61.
23. Ren X S, Kazis L E, Lee A F, Hamed A, Huang YH, Chunninghamg F et al. Patient characteristics and prescription pattern of atypical antipsychotics among patients with Schizophrenia. J Clin Pharm Ther 2002; 27:441-451.
24. Essock SM, Covell NC, Davis SM, Stroup TS, Roseneck RA, Liberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006 Dec; 163(12):2090-95.
25. Barak Y, Mireck I, Knobler HY, Natan Z, Aizenberg D. Suicidality and second generation anytipsychotics in schizophrenia patients: A case-controlled retrospective study during a 5-year period. Psychopharmacology 2004 Sep; 175(2):215-9.
26. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Fleischhacker WW. Association of olanzapine-induced weight gain with an increase in body fat. American Journal of Psychiatry. 2001 Oct 1; 158(10):1719-22.